CompletedPhase 2NCT00274352
A Study of Adalimumab to Treat Sarcoidosis of the Skin
Studying Sarcoidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pariser, Robert J., M.D.
- Principal Investigator
- Robert J Pariser, MDEastern Virginia Medical School
- Intervention
- adalimumab(drug)
- Enrollment
- 16 target
- Eligibility
- 18-89 years · All sexes
- Timeline
- 2006 – 2012
Study locations (1)
- Virginia Clinical Research, Inc., Norfolk, Virginia, United States
Collaborators
Abbott · Virginia Clinical Research, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00274352 on ClinicalTrials.govOther trials for Sarcoidosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07498842Corticosteroid Tapering in SarcoidosisRoyal Brompton & Harefield NHS Foundation Trust
- RECRUITINGNANCT07073963Virtual Patient Groups for Sarcoidosis Associated FatigueThe Cleveland Clinic
- RECRUITINGPHASE2NCT07159074Repurposing Tilmanocept for Cardiac SarcoidosisDuke University
- RECRUITINGPHASE2NCT06978725A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)Priovant Therapeutics, Inc.
- RECRUITINGNANCT05954507Evaluation of the Prognostic Value of PET/MRI in Cardiac SarcoidosisAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE2NCT06660732Rilonacept in Subjects With Cardiac SarcoidosisMayo Clinic
- RECRUITINGNANCT07384897Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung DiseaseUniversité Catholique de Louvain
- RECRUITINGNCT06510894Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose SuppressionUniversity of Pennsylvania